These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 32234759

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
    Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, Scatolini M, Chiorino G, Vergani E, Rodolfo M, Maurichi A, Posch C, Matin RN, Harwood CA, Bergamaschi D.
    Cancer Res; 2020 Jun 15; 80(12):2676-2688. PubMed ID: 32291316
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar 15; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 5. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z, Lim SY, Kefford RF, Rizos H.
    Pigment Cell Melanoma Res; 2020 Mar 15; 33(2):345-357. PubMed ID: 31518489
    [Abstract] [Full Text] [Related]

  • 6. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
    Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN.
    Clin Cancer Res; 2018 Dec 15; 24(24):6483-6494. PubMed ID: 29903896
    [Abstract] [Full Text] [Related]

  • 7. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J, Tomić I, Pavić M.
    Acta Dermatovenerol Croat; 2024 Mar 15; 32(1):75-76. PubMed ID: 38946192
    [Abstract] [Full Text] [Related]

  • 8. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.
    Clin Cancer Res; 2016 Apr 01; 22(7):1592-602. PubMed ID: 26673799
    [Abstract] [Full Text] [Related]

  • 9. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C, Fusi L, Weiss N, Goller SG, Meder K, Frings VG, Kneitz H, Goebeler M, Houben R, Schrama D, Schmidt M.
    J Invest Dermatol; 2020 Dec 01; 140(12):2455-2465.e10. PubMed ID: 32376279
    [Abstract] [Full Text] [Related]

  • 10. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L, Mazzotta A, Garofoli M, Di Fonte R, Guida G, Guida M, Tommasi S, Azzariti A.
    Biomed Pharmacother; 2021 Jan 01; 133():111006. PubMed ID: 33202284
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 12. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
    Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F.
    Sci Rep; 2022 Jan 24; 12(1):1248. PubMed ID: 35075200
    [Abstract] [Full Text] [Related]

  • 13. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
    Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, Slater A, Lau P, Meeth K, Oliaro J, Haynes N, McArthur GA, Sheppard KE.
    Sci Rep; 2019 Feb 04; 9(1):1225. PubMed ID: 30718660
    [Abstract] [Full Text] [Related]

  • 14. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W.
    Clin Cancer Res; 2013 Dec 15; 19(24):6696-702. PubMed ID: 24345920
    [Abstract] [Full Text] [Related]

  • 15. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.
    Nat Med; 2017 Aug 15; 23(8):929-937. PubMed ID: 28714990
    [Abstract] [Full Text] [Related]

  • 16. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
    Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE.
    Mol Cancer Ther; 2021 Oct 15; 20(10):2049-2060. PubMed ID: 34376578
    [Abstract] [Full Text] [Related]

  • 17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C.
    Mol Cancer; 2017 Jun 08; 16(1):102. PubMed ID: 28595656
    [Abstract] [Full Text] [Related]

  • 18. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
    Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, Tóvári J, Aigner C, Tímár J, Garay T, Hegedűs B.
    BMC Cancer; 2018 May 08; 18(1):542. PubMed ID: 29739364
    [Abstract] [Full Text] [Related]

  • 19. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 08; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 20. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 08; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.